
    
      This is a randomized, double-blind, placebo-controlled, single injection, 24-week study to
      evaluate the safety, efficacy and PK of EP-104IAR in subjects with osteoarthritis knee pain

      Following screening and baseline assessments to determine eligibility, each participant will
      receive a single IA injection of either EP-104IAR or placebo (vehicle). Participants will be
      followed up for 24 weeks following the injection for safety, PK and efficacy assessments.
    
  